Dynavax says U.S. FDA rejects its hepatitis B vaccine
Nov 14 (Reuters) - Dynavax Technologies Corp said on Monday the U.S. Food and Drug Administration had rejected the marketing application for its hepatitis B vaccine Heplisav-B, sending the company's... [Source]
Publication Date:Origin: reuters.com
Category: hotStocksNews
Topics: vaccine, hepatitis, Dynavax, company's, sending, Heplisav-B, application, the marketing, rejected, Administration, said on, Technologies, (Reuters), rejects
Source: http://feeds.reuters.com/~r/reuters/hotStocksNews/~3/2je4mKxzHWU/dynavax-techs-fda-idUSL4N1DF48A